News|Videos|November 20, 2023
HER2-Positive Endometrial Cancer: A Targeted Approach to Treatment
Author(s)Ritu Salani, MD, Bhavana Pothuri, MD
The role of HER2 status and targeted therapy with trastuzumab in advanced endometrial cancer, emphasizing the need for effective management of cardiac toxicities and comorbidities.
Advertisement
Episodes in this series
Advertisement
Related to this article
Dana Chase, MD, discusses why B7-H4 has emerged as a promising antibody-drug conjugate target in ovarian and endometrial cancer.
Advertisement
Advertisement
Trending on OncLive
1
Tam-Peli Reduces Risk of Death by 54% vs Topotecan in Relapsed SCLC
2
Ris-Rez Extends Median OS to 18.5 Months vs Topotecan in Relapsed SCLC
3
Iza-Bren Elicits 33% ORR, 6.9-Month PFS in Post-Osimertinib EGFR-Mutated NSCLC
4
Dr Liu on Building on the ADRIATIC Regimen in Limited-Stage Small Cell Lung Cancer
5